Clinical

Medical experts navigate significant challenges associated with PNH treatment.

Investigators hoped to use large-scale proteomics to help predict hypertensive disorders of pregnancy (HDP), using blood proteins obtained from individuals in their first trimester of pregnancy—but success has been elusive.

The therapy led to increased frataxin levels and decreased left ventricular mass in patients with Friedreich ataxia (FA) cardiomyopathy, the authors said.

Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.

Using the modified Tinkertoy Test (m-TTT), recent findings further the understanding of specific cognitive deficits affecting life skills in individuals with schizophrenia, revealing a critical link between divergent thinking and daily functioning.

An expert consensus by Spanish dermatologists offers treatment recommendations for androgenetic alopecia, the most common cause of hair loss, using a combination of medications and hair transplantation depending on the patient's sex, age, and other factors.

A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

With 20 hospitals earning the Honor Roll distinction, the report compared hospitals in 15 specialties and 20 procedures and conditions. Of these, only 160 earned the "Best Hospitals" ranking, signifying excellence in clinical outcomes, nursing care, and patient safety practices.

The biomarker, G-protein-coupled receptor 176 (GPR176), may be a driver in the progression of ovarian cancer and potential target for gene therapy, suggested researchers of a new study.

No significant differences in efficacy or safety of 2 aspirin doses were found between male and female patients for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

Overall and site-specific colorectal cancer (CRC) had a negative association with the usage of aspirin.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers.

A Danish study found that living in cities with fewer than 50,000 residents and in newer, owned, and less dense homes is associated with a lower risk of developing chronic obstructive pulmonary disease (COPD).

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

Patients with both diabetes and atherosclerotic cardiovascular disease (ASCVD) have about 1.5 times higher total direct health care expenditures than those without diabetes.

A new study has found that myasthenia gravis does not affect the long-term prognosis of patients with thymoma.

A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.

Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM).

While there have been advances in screening technology, it is crucial to continue investing in emerging modalities and to ensure these advancements translate to clinical practice.

CMS recently launched a voluntary, nationwide dementia care program; the number of physicians who reported at least 1 symptom of burnout has dropped below 50% for the first time since the onset of the COVID-19 pandemic; diabetes drugs have all been in short supply over the last 18 months, partly due to people using them off label for weight loss.

Key considerations for transfusion requirements in patients with PNH are discussed by key opinion leaders.